Brought to you by 
Bertek gets rights to Janssen beta blocker
24 Apr 2001
Executive Summary
J&J's Janssen unit will license Bertek Pharmaceuticals (Mylan's branded products division) exclusive rights in the US and Canada to nebivolol, a beta blocker it developed in the late 1980s.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bertek gets rights to Janssen beta blocker
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice